Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
7 "Yeon Sil Kim"
Filter
Filter
Article category
Keywords
Publication year
Authors
Original Articles
SUVmax Predicts Disease Progression after Stereotactic Ablative Radiotherapy in Stage I Non-small Cell Lung Cancer
Yoo-Kang Kwak, Hee Hyun Park, Kyu Hye Choi, Eun Young Park, Soo Yoon Sung, Sea-Won Lee, Ji Hyun Hong, Hyo Chun Lee, Ie Ryung Yoo, Yeon Sil Kim
Cancer Res Treat. 2020;52(1):85-97.   Published online May 17, 2019
DOI: https://doi.org/10.4143/crt.2019.007
AbstractAbstract PDFPubReaderePub
Purpose
Fluorodeoxyglucose positron emission tomography–computed tomography (PET-CT) is gaining evidence as a predictive factor in non-small cell lung cancer (NSCLC). Stereotactic ablative radiotherapy (SABR) is the standard treatment in early-stage NSCLC when a patient is unsuitable for surgery. We performed a study to assess the prognostic clinical significance of PET-CT after SABR in early-stage NSCLC.
Materials and Methods
Seventy-six patients with stage I NSCLC treated with SABR were investigated. Total radiation dose ranged from 36 to 63 Gy in three to eight fractions depending on tumor location and size. Respiratory motion control was implemented at simulation and during treatment. PET-CT prior to SABR was performed in 66 patients (86.8%).
Results
Median follow-up time was 32 months (range, 5 to 142 months). Local control rate at 1, 2, and 5 years were 95.9%, 92.8%, and 86.7%, respectively. Overall survival (OS) at 1, 2, and 5 years were 91.0%, 71.3%, and 52.1% respectively. Cause-specific survival at 1, 2, and 5 years were 98.6%, 93.1%, and 84.3% respectively. Tumor size and pre-SABR maximal standardized uptake value (SUVmax) demonstrated statistical significance in the Kaplan-Meier survival analyses with log-rank test. In multivariate analyses pre-SABR SUVmax remained statistically significant in correlation to OS (p=0.024; hazard ratio [HR], 3.2; 95% confidence interval [CI], 1.2 to 8.8) and with marginal significance in regards to regional progression-free survival (p=0.059; HR, 32.5; 95% CI, 2.6 to 402.5).
Conclusion
Pre-SABR SUVmax demonstrated a predictive power in statistical analyses. Tumors with SUVmax above 6 at diagnosis were associated with inferior outcomes.

Citations

Citations to this article as recorded by  
  • Enhanced NSCLC subtyping and staging through attention-augmented multi-task deep learning: A novel diagnostic tool
    Runhuang Yang, Weiming Li, Siqi Yu, Zhiyuan Wu, Haiping Zhang, Xiangtong Liu, Lixin Tao, Xia Li, Jian Huang, Xiuhua Guo
    International Journal of Medical Informatics.2025; 193: 105694.     CrossRef
  • Invasive Nodal Staging via Endobronchial Ultrasound and Outcome in Patients Treated with Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer – Results from a Single Institution Study
    Benjamin George, Atallah Baydoun, Samar Bhat, Lauryn Bailey, Theodore Arsenault, Yilun Sun, Yuxia Zhang, Yiran Zheng, Prashant Vempati, Tarun Podder, Tithi Biswas
    Clinical Lung Cancer.2024; 25(4): e181.     CrossRef
  • Prognostic value of consolidation-to-tumor ratio on computed tomography in NSCLC: a meta-analysis
    Yongming Wu, Wenpeng Song, Denian Wang, Junke Chang, Yan Wang, Jie Tian, Sicheng Zhou, Yingxian Dong, Jing Zhou, Jue Li, Ziyi Zhao, Guowei Che
    World Journal of Surgical Oncology.2023;[Epub]     CrossRef
  • Tumor to liver maximum standardized uptake value ratio of FDG-PET/CT parameters predicts tumor treatment response and survival of stage III non-small cell lung cancer
    Pengfei Zhang, Wei Chen, Kewei Zhao, Xiaowen Qiu, Tao Li, Xingzhuang Zhu, Peng Sun, Chunsheng Wang, Yipeng Song
    BMC Medical Imaging.2023;[Epub]     CrossRef
  • Evaluation of response to stereotactic body radiation therapy for nonsmall cell lung cancer: PET response criteria in solid tumors versus response evaluation criteria in solid tumors
    Jixia Han, Qi Song, Feng Guo, Rui Du, Henghu Fang, Jingbo Kang, Zejun Lu
    Nuclear Medicine Communications.2022;[Epub]     CrossRef
  • Assessing tumor angiogenesis using dynamic contrast-enhanced integrated magnetic resonance-positron emission tomography in patients with non-small-cell lung cancer
    Yu-Sen Huang, Jenny Ling-Yu Chen, Hsin-Ming Chen, Li-Hao Yeh, Jin-Yuan Shih, Ruoh-Fang Yen, Yeun-Chung Chang
    BMC Cancer.2021;[Epub]     CrossRef
  • Potential role of functional imaging in predicting outcome for patients treated with carbon ion therapy: a review
    Giulia Riva, Sara Imparato, Giovanni Savietto, Mattia Pecorilla, Alberto Iannalfi, Amelia Barcellini, Sara Ronchi, Maria Rosaria Fiore, Chiara Paganelli, Giulia Buizza, Mario Ciocca, Guido Baroni, Lorenzo Preda, Ester Orlandi
    The British Journal of Radiology.2021;[Epub]     CrossRef
  • Prognostic value of metabolic signature on 18F-FDG uptake in breast cancer patients after radiotherapy
    Jin Meng, Emmanuel Deshayes, Li Zhang, Wei Shi, Xiaomeng Zhang, Xingxing Chen, Xin Mei, Jinli Ma, Yizhou Jiang, Jiong Wu, Zhimin Shao, Xiaoli Yu, Zhaozhi Yang, Xiaomao Guo
    Molecular Therapy - Oncolytics.2021; 23: 412.     CrossRef
  • Parámetros cuantitativos de la PET/TC con 18F-FDG como factores pronósticos en el cáncer de pulmón localizado e inoperable
    J.R. Infante, J. Cabrera, J.I. Rayo, C. Cruz, J. Serrano, M. Moreno, A. Martínez, P. Jiménez, A. Cobo
    Revista Española de Medicina Nuclear e Imagen Molecular.2020; 39(6): 353.     CrossRef
  • 18F-FDG PET/CT quantitative parameters as prognostic factors in localized and inoperable lung cancer
    J.R. Infante, J. Cabrera, J.I. Rayo, C. Cruz, J. Serrano, M Moreno, A. Martínez, P. Jiménez, A. Cobo
    Revista Española de Medicina Nuclear e Imagen Molecular (English Edition).2020; 39(6): 353.     CrossRef
  • 7,354 View
  • 133 Download
  • 9 Web of Science
  • 10 Crossref
Close layer
Dummy Run of Quality Assurance Program before Prospective Study of Hippocampus-Sparing Whole-Brain Radiotherapy and Simultaneous Integrated Boost for Multiple Brain Metastases from Non-small Cell Lung Cancer: Korean Radiation Oncology Group (KROG) 17-06 Study
Eunah Chung, Jae Myoung Noh, Kyu Chan Lee, Jin Hee Kim, Weon Kuu Chung, Yang-Gun Suh, Jung Ae Lee, Ki Ho Seol, Hong Gyun Wu, Yeon Sil Kim, O Kyu Noh, Jae Won Park, Dong Soo Lee, Jihae Lee, Young Suk Kim, Woo-Yoon Park, Min Kyu Kang, Sunmi Jo, Yong Chan Ahn
Cancer Res Treat. 2019;51(3):1001-1010.   Published online October 15, 2018
DOI: https://doi.org/10.4143/crt.2018.415
AbstractAbstract PDFPubReaderePub
Purpose
Lung Cancer Subcommittee of Korean Radiation Oncology Group (KROG) has recently launched a prospective clinical trial (KROG 17-06) of hippocampus-sparing whole brain radiotherapy (HS-WBRT) with simultaneous integrated boost (SIB) in treating multiple brain metastases from non-small cell lung cancer. In order to improve trial quality, dummy run studies among the participating institutions were designed. This work reported the results of two-step dummy run procedures of the KROG 17-06 study.
Materials and Methods
Two steps tested hippocampus contouring variability and radiation therapy planning compliance. In the first step, the variation of the hippocampus delineation was investigated for two representative cases using the Dice similarity coefficients. In the second step, the participating institutions were requested to generate a HS-WBRT with SIB treatment plan for another representative case. The compliance of the treatment plans to the planning protocol was evaluated.
Results
In the first step, the median Dice similarity coefficients of the hippocampus contours for two other dummy run cases changed from 0.669 (range, 0.073 to 0.712) to 0.690 (range, 0.522 to 0.750) and from 0.291 (range, 0.219 to 0.522) to 0.412 (range, 0.264 to 0.598) after providing the hippocampus contouring feedback. In the second step, with providing additional plan priority and extended dose constraints to the target volumes and normal structures, we observed the improved compliance of the treatment plans to the planning protocol.
Conclusion
The dummy run studies demonstrated the notable inter-institutional variability in delineating the hippocampus and treatment plan generation, which could be decreased through feedback from the trial center.

Citations

Citations to this article as recorded by  
  • Radiotherapy trial quality assurance processes: a systematic review
    Chloe Brooks, Elizabeth Miles, Peter J Hoskin
    The Lancet Oncology.2024; 25(3): e104.     CrossRef
  • Durvalumab with chemoradiotherapy for limited-stage small-cell lung cancer
    Sehhoon Park, Jae Myoung Noh, Yoon-La Choi, Sang Ah Chi, Kyunga Kim, Hyun Ae Jung, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn, Jong-Mu Sun
    European Journal of Cancer.2022; 169: 42.     CrossRef
  • Region-Specific Effects of Fractionated Low-Dose Versus Single-Dose Radiation on Hippocampal Neurogenesis and Neuroinflammation
    Zoé Schmal, Claudia E. Rübe
    Cancers.2022; 14(22): 5477.     CrossRef
  • Non–coplanar whole brain radiotherapy is an effective modality for parotid sparing
    Jaehyeon Park, Jae Won Park, Ji Woon Yea
    Yeungnam University Journal of Medicine.2019; 36(1): 36.     CrossRef
  • 8,930 View
  • 286 Download
  • 4 Web of Science
  • 4 Crossref
Close layer
Survey of the Patterns of Using Stereotactic Ablative Radiotherapy for Early-Stage Non-small Cell Lung Cancer in Korea
Sanghyuk Song, Ji Hyun Chang, Hak Jae Kim, Yeon Sil Kim, Jin Hee Kim, Yong Chan Ahn, Jae-Sung Kim, Si Yeol Song, Sung Ho Moon, Moon June Cho, Seon Min Youn
Cancer Res Treat. 2017;49(3):688-694.   Published online October 31, 2016
DOI: https://doi.org/10.4143/crt.2016.219
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Stereotactic ablative radiotherapy (SABR) is an effective emerging technique for early-stage non-small cell lung cancer (NSCLC). We investigated the current practice of SABR for early-stage NSCLC in Korea.
Materials and Methods
We conducted a nationwide survey of SABR for NSCLC by sending e-mails to all board-certified members of the Korean Society for Radiation Oncology. The survey included 23 questions focusing on the technical aspects of SABR and 18 questions seeking the participants’ opinions on specific clinical scenarios in the use of SABR for early-stage NSCLC. Overall, 79 radiation oncologists at 61/85 specialist hospitals in Korea (71.8%) responded to the survey.
Results
SABR was used at 33 institutions (54%) to treat NSCLC. Regarding technical aspects, the most common planning methods were the rotational intensity-modulated technique (59%) and the static intensity-modulated technique (49%). Respiratory motion was managed by gating (54%) or abdominal compression (51%), and 86% of the planning scans were obtained using 4-dimensional computed tomography. In the clinical scenarios, the most commonly chosen fractionation schedule for peripherally located T1 NSCLC was 60 Gy in four fractions. For centrally located tumors and T2 NSCLC, the oncologists tended to avoid SABR for radiotherapy, and extended the fractionation schedule.
Conclusion
The results of our survey indicated that SABR is increasingly being used to treat NSCLC in Korea. However, there were wide variations in the technical protocols and fractionation schedules of SABR for early-stage NSCLC among institutions. Standardization of SABR is necessary before implementing nationwide, multicenter, randomized studies.

Citations

Citations to this article as recorded by  
  • Guidelines for safe practice of stereotactic body (ablative) radiation therapy: RANZCR 2023 update
    Howard Yu‐hao Liu, Nicholas Hardcastle, Michael Bailey, Shankar Siva, Anna Seeley, Tamara Barry, Jeremy Booth, Louis Lao, Michelle Roach, Stacey Buxton, David Thwaites, Matthew Foote
    Journal of Medical Imaging and Radiation Oncology.2024; 68(2): 217.     CrossRef
  • Technical Giants But Biologic Infants: Defining a More Sophisticated Role for Local Therapy in Metastatic Disease
    Sophia C. Kamran, David Palma, Matthew S. Katz, Anthony L. Zietman
    Seminars in Radiation Oncology.2021; 31(3): 200.     CrossRef
  • MiR-223-3p regulates cell viability, migration, invasion, and apoptosis of non-small cell lung cancer cells by targeting RHOB
    Shufang Li, Yuping Feng, Yuxia Huang, Yu Liu, Yanxi Wang, Yan Liang, Hui Zeng, Hong Qu, Ling Wei
    Open Life Sciences.2020; 15(1): 389.     CrossRef
  • 9,980 View
  • 235 Download
  • 3 Web of Science
  • 3 Crossref
Close layer
Predictors of Distant Metastasis after Radical Surgery Followed by Postoperative Radiotherapy with or without Chemotherapy for Oropharyngeal Cancer
Mi Joo Chung, Yeon Sil Kim, Ji Yoon Kim, Yun Hee Lee, Ji Hyun Jang, Jin Hyoung Kang, Ie Ryung Yoo, Youn Soo Lee
Cancer Res Treat. 2016;48(4):1167-1176.   Published online March 3, 2016
DOI: https://doi.org/10.4143/crt.2015.379
AbstractAbstract PDFPubReaderePub
Purpose
We investigated the prognostic factors for distant metastasis (DM) in patients with locally advanced oropharyngeal cancer (OPC) treated with surgery and adjuvant radiotherapy with or without concurrent chemotherapy.
Materials and Methods
Eighty-five patients treated between January 1995 and August 2014 were evaluated retrospectively. Data regarding the pathological tumour and nodal status, human papillomavirus (HPV) status, treatment characteristics, and pretreatment maximum standardized uptake value (SUVmax) of 18-fluoro-2-deoxyglucose positron emission tomography–computed tomography scan (18F-FDG PET-CT) were evaluated, and their influence on DM and survival outcomes were analyzed.
Results
Median follow-up period was 48.0 months. Recurrence was observed in 20 patients, including locoregional recurrence and DM. DM was observed in 13 patients. A multivariate analysis confirmed that the presence of lymphovascular invasion (p=0.031), lower neck lymph node (LN) involvement (p=0.006), SUVmax ≥ 9.7 (p=0.014), and tumour size ≥ 3 cm (p=0.037) significantly affected DM. HPV status was not associated with DM. Perineural invasion (p=0.048), lower neck LNinvolvement (p=0.008), SUVmax ≥ 9.7 (p=0.019), and tumour size ≥ 3 cm (p=0.033) were also significant factors for the DM-free survival rate.
Conclusion
Lower neck LN involvement, high SUVmax in pretreatment 18F-FDG PET-CT, and large tumour size were predictive factors for DM in patients of OPC.

Citations

Citations to this article as recorded by  
  • An open, multicenter, exploratory study of apatinib mesylate maintenance therapy for recurrent/metastatic head and neck squamous cell carcinoma (ChiCTR1800019375)
    Jinlong Wei, Jing Su, Jianfeng Wang, Xiaojing Jia, Qin Zhao, Weiyan Shi, Huanhuan Wang, Zhuangzhuang Zheng, Xin Jiang
    Head & Neck.2024; 46(4): 915.     CrossRef
  • The Prognostic Role of Perineural Invasion for Survival in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis
    Zhuo-Ying Tao, Guang Chu, Yu-Xiong Su
    Cancers.2024; 16(14): 2514.     CrossRef
  • Management of Recurrent HPV-Positive Oropharyngeal Squamous Cell Carcinoma: a Contemporary Review
    Sam Dowthwaite, James Jackson, Marcin Dzienis, Eric Khoo, Mathew Cronin, Emily Guazzo
    Current Oncology Reports.2023; 25(5): 501.     CrossRef
  • A Mn-doped calcium phosphate nanoparticle-based multifunctional nanocarrier for targeted drug delivery and cellular MR imaging
    Chaohui Zhou, Shenglei Hou, Chusen Huang, Nengqin Jia
    Journal of Nanoparticle Research.2022;[Epub]     CrossRef
  • Importance of lymph node ratio in HPV-related oropharyngeal cancer patients treated with surgery and adjuvant treatment
    Kyu Hye Choi, Jin Ho Song, Ji Hyun Hong, Youn Soo Lee, Jin Hyoung Kang, Dong-Il Sun, Min-Sik Kim, Yeon-Sil Kim, Yifei Wang
    PLOS ONE.2022; 17(8): e0273059.     CrossRef
  • 18F-FDG PET/CT–Based Prognostic Survival Model After Surgery for Head and Neck Cancer
    Gwenaelle Creff, Franck Jegoux, Xavier Palard, Adrien Depeursinge, Ronan Abgral, Remi Marianowski, Jean-Christophe Leclere, Thomas Eugene, Olivier Malard, Renaud De Crevoisier, Anne Devillers, Joel Castelli
    Journal of Nuclear Medicine.2022; 63(9): 1378.     CrossRef
  • Risk stratification of postoperative recurrence in hypopharyngeal squamous-cell carcinoma patients with nodal metastasis
    Hanqing Lin, Tian Wang, Yu Heng, Xiaoke Zhu, Liang Zhou, Ming Zhang, Yong Shi, Pengyu Cao, Lei Tao
    Journal of Cancer Research and Clinical Oncology.2021; 147(3): 803.     CrossRef
  • A two-fold interpenetration pillar-layered metal-organic frameworks based on BODIPY for chemo-photodynamic therapy
    Yang Meng, Yingying Du, Yanxin Lin, Yu Su, Ruonan Li, Yaqing Feng, Shuxian Meng
    Dyes and Pigments.2021; 188: 109174.     CrossRef
  • Current Updates on Cancer-Causing Types of Human Papillomaviruses (HPVs) in East, Southeast, and South Asia
    Chichao Xia, Sile Li, Teng Long, Zigui Chen, Paul K. S. Chan, Siaw Shi Boon
    Cancers.2021; 13(11): 2691.     CrossRef
  • Evaluation of the Prognostic Value of FDG PET/CT Parameters for Patients With Surgically Treated Head and Neck Cancer
    Gwenaelle Creff, Anne Devillers, Adrien Depeursinge, Xavier Palard-Novello, Oscar Acosta, Franck Jegoux, Joel Castelli
    JAMA Otolaryngology–Head & Neck Surgery.2020; 146(5): 471.     CrossRef
  • Sequentially self-assembled polysaccharide-based nanocomplexes for combined chemotherapy and photodynamic therapy of breast cancer
    Yaping Wang, Ming Yang, Junmin Qian, Weijun Xu, Jinlei Wang, Guanghui Hou, Lijie Ji, Aili Suo
    Carbohydrate Polymers.2019; 203: 203.     CrossRef
  • Self-assembly of photosensitive and chemotherapeutic drugs for combined photodynamic-chemo cancer therapy with real-time tracing property
    Shengtao Wang, Jingtao Li, Zhou Ye, Jieling Li, Anhe Wang, Jing Hu, Shuo Bai, Jian Yin
    Colloids and Surfaces A: Physicochemical and Engineering Aspects.2019; 574: 44.     CrossRef
  • Patterns of recurrence in oral tongue cancer with perineural invasion
    Jennifer R. Cracchiolo, Bin Xu, Jocelyn C. Migliacci, Nora Katabi, David G. Pfister, Nancy Y. Lee, Snehal G. Patel, Ronald A. Ghossein, Richard J. Wong
    Head & Neck.2018; 40(6): 1287.     CrossRef
  • Targeted Chemo-Photodynamic Combination Platform Based on the DOX Prodrug Nanoparticles for Enhanced Cancer Therapy
    Yumin Zhang, Fan Huang, Chunhua Ren, Lijun Yang, Jianfeng Liu, Zhen Cheng, Liping Chu, Jinjian Liu
    ACS Applied Materials & Interfaces.2017; 9(15): 13016.     CrossRef
  • 10,790 View
  • 220 Download
  • 10 Web of Science
  • 14 Crossref
Close layer
Interstitial Lung Change in Pre-radiation Therapy Computed Tomography Is a Risk Factor for Severe Radiation Pneumonitis
Yun Hee Lee, Yeon Sil Kim, Sang Nam Lee, Hyo Chun Lee, Se Jin Oh, Seoung Joon Kim, Young Kyoon Kim, Dae Hee Han, Ie Ryung Yoo, Jin Hyung Kang, Suk Hee Hong
Cancer Res Treat. 2015;47(4):676-686.   Published online February 13, 2015
DOI: https://doi.org/10.4143/crt.2014.180
AbstractAbstract PDFPubReaderePub
Purpose
We examined clinical and dosimetric factors as predictors of symptomatic radiation pneumonitis (RP) in lung cancer patients and evaluated the relationship between interstitial lung changes in the pre-radiotherapy (RT) computed tomography (CT) and symptomatic RP. Materials and Methods Medical records and dose volume histogram data of 60 lung cancer patients from August 2005 to July 2006 were analyzed. All patients were treated with three dimensional (3D) conformal RT of median 56.9 Gy. We assessed the association of symptomatic RP with clinical and dosimetric factors.
Results
With a median follow-up of 15.5 months (range, 6.1 to 40.9 months), Radiation Therapy Oncology Group grade ≥ 2 RP was observed in 14 patients (23.3%). Five patients (8.3%) died from RP. The interstitial changes in the pre-RT chest CT, mean lung dose (MLD), and V30 significantly predicted RP in multivariable analysis (p=0.009, p < 0.001, and p < 0.001, respectively). MLD, V20, V30, and normal tissue complication probability normal tissue complication probability (NTCP) were associated with the RP grade but less so for grade 5 RP. The risk of RP grade ≥ 2, ≥ 3, or ≥ 4 was higher in the patients with interstitial lung change (grade 2, 15.6% to 46.7%, p=0.03; grade 3, 4.4% to 40%, p=0.002; grade 4, 4.4% to 33.3%, p=0.008). Four of the grade 5 RP patients had diffuse interstitial change in pre-RT CT and received chemoradiotherapy. Conclusion Our study identified diffuse interstitial disease as a significant clinical risk for RP, particularly fatal RP. We showed the usefulness of MLD, V20, V30, and NTCP in predicting the incidence and severity of RP.

Citations

Citations to this article as recorded by  
  • Safety and Efficacy of Single-Fraction Carbon-Ion Radiotherapy for Early-Stage Lung Cancer with Interstitial Pneumonia
    Shuri Aoki, Hitoshi Ishikawa, Mio Nakajima, Naoyoshi Yamamoto, Shinichiro Mori, Tokuhiko Omatsu, Yuji Tada, Teruaki Mizobuchi, Satoshi Ikeda, Ichiro Yoshino, Shigeru Yamada
    Cancers.2024; 16(3): 562.     CrossRef
  • Research Progress of Idiopathic Pulmonary Fibrosis Complicated with Lung Cancer
    Hao Ruan, Zihui Zhang, Jiao Tian, Mingjiang Li, Ting Xiao
    International Journal of Cancer Management.2024;[Epub]     CrossRef
  • Drug change from nintedanib to pirfenidone for the perioperative management of lung cancer with idiopathic pulmonary fibrosis: A case report
    Yukiko Matsui, Mitsuhiro Abe, Yasufumi Uematsu, Yuki Onozato, Takayoshi Yamamoto, Takekazu Iwata
    The Journal of the Japanese Association for Chest Surgery.2024; 38(5): 446.     CrossRef
  • Preliminary Results of Developing Imaging Complexity Biomarkers for the Incidence of Severe Radiation Pneumonitis Following Radiotherapy in Non-Small Cell Lung Cancer Patients with Underlying Idiopathic Pulmonary Fibrosis
    Jeongeun Hwang, Hakyoung Kim, Sun Myung Kim, Dae Sik Yang
    Life.2024; 14(7): 897.     CrossRef
  • CT-based different regions of interest radiomics analysis for acute radiation pneumonitis in patients with locally advanced NSCLC after chemoradiotherapy
    Liqiao Hou, Kuifei Chen, Chao Zhou, Xingni Tang, Changhui Yu, Haijian Jia, Qianyi Xu, Suna Zhou, Haihua Yang
    Clinical and Translational Radiation Oncology.2024; 48: 100828.     CrossRef
  • Computed tomography patterns and clinical outcomes of radiation pneumonitis in non–small-cell lung cancer patients
    Ji Hoon Choi, Hee Kang, Ji Su Lim, Ki-Nam Lee
    Acta Radiologica Open.2024;[Epub]     CrossRef
  • Populations particulières : impact de l’état général et des principales comorbidités et de leurs traitements sur la prise en charge thérapeutique locale des patients présentant un Cancer Bronchique Non à Petites Cellules
    V. Gounant, R. Ezzedine, B. Duchemann, T. Pierret, S. Brosseau, Y. Castier, G. Zalcman, P. Mordant
    Revue des Maladies Respiratoires Actualités.2024; 16(2): 2S290.     CrossRef
  • Development of Imaging Complexity Biomarkers for Prediction of Symptomatic Radiation Pneumonitis in Patients with Non-Small Cell Lung Cancer, Focusing on Underlying Lung Disease
    Jeongeun Hwang, Hakyoung Kim, Joon-Young Moon, Sun Myung Kim, Dae Sik Yang
    Life.2024; 14(11): 1497.     CrossRef
  • Longitudinal microcomputed tomography detects onset and progression of pulmonary fibrosis in conditional Nedd4-2 deficient mice
    Dominik H. W. Leitz, Philip Konietzke, Willi L. Wagner, Mara Mertiny, Claudia Benke, Thomas Schneider, Rory E. Morty, Christian Dullin, Wolfram Stiller, Hans-Ulrich Kauczor, Marcus A. Mall, Julia Duerr, Mark O. Wielpütz
    American Journal of Physiology-Lung Cellular and Molecular Physiology.2024; 327(6): L917.     CrossRef
  • Stereotactic body radiation therapy (SBRT) as salvage treatment for early stage lung cancer with interstitial lung disease (ILD): An observational and exploratory case series of non-asian patients
    J. Pluvy, A. Zaccariotto, P. Habert, J. Bermudez, A. Mogenet, J.Y. Gaubert, P. Tomasini, L. Padovani, L. Greillier
    Respiratory Medicine and Research.2023; 83: 100984.     CrossRef
  • Predictors of high-grade radiation pneumonitis following radiochemotherapy for locally advanced non-small cell lung cancer: analysis of clinical, radiographic and radiotherapy-related factors
    Elisabeth Weiss, Anthony Ricco, Nitai Mukhopadhyay, Leila Rezai Gharai, Xiaoyan Deng, Nuzhat Jan, Christopher Guy
    Journal of Radiotherapy in Practice.2023;[Epub]     CrossRef
  • Impact of palliative radiotherapy with or without lung irradiation in patients with interstitial lung disease
    Kenji Makita, Yasushi Hamamoto, Hiromitsu Kanzaki, Kei Nagasaki, Yoshifumi Sugawara, Toshiyuki Kozuki
    Radiotherapy and Oncology.2023; 183: 109636.     CrossRef
  • Combined radiation- and immune checkpoint-inhibitor-induced pneumonitis – The challenge to predict and detect overlapping immune-related adverse effects from evolving laboratory biomarkers and clinical imaging
    Nika Guberina, Florian Wirsdörfer, Martin Stuschke, Verena Jendrossek
    Neoplasia.2023; 39: 100892.     CrossRef
  • Immunotherapy-related pneumonitis and the synergic impact of thoracic radiation and preexisting interstitial lung disease
    Maria Azhar, Rodeo Abrencillo, Saumil Gandhi, Mehmet Altan, Ajay Sheshadri
    Current Opinion in Pulmonary Medicine.2023; 29(4): 248.     CrossRef
  • Cancers pulmonaires associés à une pathologie interstitielle pulmonaire fibrosante
    B. Duchemann, J. Cadranel, A. Paix, L. Matton, M. Didier, D. Radu, M. Kambouchner, O. Freynet, K. Chouanhia, P.Y. Brillet, H. Nunes
    Revue des Maladies Respiratoires Actualités.2023; 15(2): 2S214.     CrossRef
  • Risk factor analysis of the development of severe radiation pneumonitis in patients with non-small cell lung cancer treated with curative radiotherapy, with focus on underlying pulmonary disease
    Hakyoung Kim, Jeongeun Hwang, Sun Myung Kim, Juwhan Choi, Dae Sik Yang
    BMC Cancer.2023;[Epub]     CrossRef
  • Quantification of diffuse parenchymal lung disease in non‐small cell lung cancer patients with definitive concurrent chemoradiation therapy for predicting radiation pneumonitis
    Ye Chan An, Jong Hoon Kim, Jae Myung Noh, Kyung Mi Yang, You Jin Oh, Sung Goo Park, Hong Ryul Pyo, Ho Yun Lee
    Thoracic Cancer.2023; 14(36): 3530.     CrossRef
  • Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer
    Hiroshi Mayahara, Kazuyuki Uehara, Aya Harada, Keiji Kitatani, Tomonori Yabuuchi, Shuichirou Miyazaki, Takeaki Ishihara, Hiroki Kawaguchi, Hikaru Kubota, Hideaki Okada, Taira Ninomaru, Chihiro Shindo, Akito Hata
    Radiation Oncology.2022;[Epub]     CrossRef
  • Palliative radiotherapy for cancer patients with interstitial lung disease: A physician's perspective
    Satoshi Ikeda
    Radiotherapy and Oncology.2022; 169: 155.     CrossRef
  • Is Thoracic Radiotherapy an Absolute Contraindication for Treatment of Lung Cancer Patients With Interstitial Lung Disease? A Systematic Review
    A. Saha, P. Dickinson, R.K. Shrimali, A. Salem, S. Agarwal
    Clinical Oncology.2022; 34(12): e493.     CrossRef
  • Prospective Study of Proton Therapy for Lung Cancer Patients with Poor Lung Function or Pulmonary Fibrosis
    Jae Myoung Noh, Hongseok Yoo, Woojin Lee, Hye Yun Park, Sun Hye Shin, Hongryull Pyo
    Cancers.2022; 14(6): 1445.     CrossRef
  • Outcomes of proton therapy for non-small cell lung cancer in patients with interstitial pneumonia
    Shingo Hashimoto, Hiromitsu Iwata, Yukiko Hattori, Koichiro Nakajima, Kento Nomura, Kensuke Hayashi, Toshiyuki Toshito, Eiko Yamamori, Kenji Akita, Jun-etsu Mizoe, Hiroyuki Ogino, Yuta Shibamoto
    Radiation Oncology.2022;[Epub]     CrossRef
  • Cancers pulmonaires associés à une pathologie interstitielle pulmonaire fibrosante
    B. Duchemann, A. Paix, L. Matton, M. Didier, D. Radu, M. Kambouchner, O. Freynet, K. Chouahnia, P.-Y. Brillet, H. Nunes
    Revue des Maladies Respiratoires Actualités.2022; 14(2): 2S378.     CrossRef
  • Quantitative Assessment and Comparative Analysis of Longitudinal Lung CT Scans of Chest-Irradiated Nonhuman Primates
    Priyanka Thakur, John D. Olson, Gregory O Dugan, J. Daniel Bourland, Nancy D. Kock, J. Mark Cline
    Radiation Research.2022;[Epub]     CrossRef
  • An Evaluation of Potent Radioprotective Effect of Dimethyl Sulfoxide for Acute Radiation-Induced Lung Injury: Tc99m-DTPA Transalveolar Clearance Scintigraphy Correlated by Histopathologic Findings
    Bengu DEPBOYLU
    Muğla Sıtkı Koçman Üniversitesi Tıp Dergisi.2022; 9(3): 266.     CrossRef
  • Usefulness of Simple Original Interstitial Lung Abnormality Scores for Predicting Radiation Pneumonitis Requiring Steroidal Treatment After Definitive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer
    Tairo Kashihara, Yuko Nakayama, Kimiteru Ito, Yuko Kubo, Kae Okuma, Satoshi Shima, Satoshi Nakamura, Kana Takahashi, Koji Inaba, Naoya Murakami, Hiroshi Igaki, Yuichiro Ohe, Masahiko Kusumoto, Jun Itami
    Advances in Radiation Oncology.2021; 6(1): 100606.     CrossRef
  • Idiopathic pulmonary fibrosis: Current knowledge, future perspectives and its importance in radiation oncology
    Görkem Türkkan, Yves Willems, Lizza E.L. Hendriks, Rémy Mostard, Lennart Conemans, Hester A Gietema, Cristina Mitea, Stéphanie Peeters, Dirk De Ruysscher
    Radiotherapy and Oncology.2021; 155: 269.     CrossRef
  • Radiation-induced lung injury: current evidence
    Marisol Arroyo-Hernández, Federico Maldonado, Francisco Lozano-Ruiz, Wendy Muñoz-Montaño, Mónica Nuñez-Baez, Oscar Arrieta
    BMC Pulmonary Medicine.2021;[Epub]     CrossRef
  • Clinical and Dosimetric Predictors of Radiation Pneumonitis in Patients With Non-Small Cell Lung Cancer Undergoing Postoperative Radiation Therapy
    Annemarie F. Shepherd, Michelle Iocolano, Jonathan Leeman, Brandon S. Imber, Aaron T. Wild, Michael Offin, Jamie E. Chaft, James Huang, Andreas Rimner, Abraham J. Wu, Daphna Y. Gelblum, Narek Shaverdian, Charles B. Simone, Daniel R. Gomez, Ellen D. Yorke,
    Practical Radiation Oncology.2021; 11(1): e52.     CrossRef
  • Scarred Lung. An Update on Radiation-Induced Pulmonary Fibrosis
    Natalia Jarzebska, Ekaterina S. Karetnikova, Alexander G. Markov, Michael Kasper, Roman N. Rodionov, Peter M. Spieth
    Frontiers in Medicine.2021;[Epub]     CrossRef
  • Impact of idiopathic pulmonary fibrosis on clinical outcomes of lung cancer patients
    Ho Cheol Kim, Seonjeong Lee, Jin Woo Song
    Scientific Reports.2021;[Epub]     CrossRef
  • Risk factors for radiation pneumonitis in lung cancer patients with subclinical interstitial lung disease after thoracic radiation therapy
    Fangjuan Li, Hui Liu, Hongyu Wu, Shixiong Liang, Yaping Xu
    Radiation Oncology.2021;[Epub]     CrossRef
  • Radiation pneumonitis after palliative radiotherapy in cancer patients with interstitial lung disease
    Masayuki Okumura, Hidehiro Hojo, Masaki Nakamura, Takashi Hiyama, Naoki Nakamura, Sadamoto Zenda, Atsushi Motegi, Yasuhiro Hirano, Shun-Ichiro Kageyama, Raturi Vijay Parshuram, Takeshi Fujisawa, Hirofumi Kuno, Tetsuo Akimoto
    Radiotherapy and Oncology.2021; 161: 47.     CrossRef
  • Clinical Outcomes of Pencil Beam Scanning Proton Therapy in Locally Advanced Non-Small Cell Lung Cancer: Propensity Score Analysis
    Nalee Kim, Jae Myoung Noh, Woojin Lee, Byoungsuk Park, Hongryull Pyo
    Cancers.2021; 13(14): 3497.     CrossRef
  • Survival analysis in lung cancer patients with interstitial lung disease
    Hassan Alomaish, Yee Ung, Stella Wang, Pascal N. Tyrrell, Saly Abo Zahra, Anastasia Oikonomou, Claudia Staab-Weijnitz
    PLOS ONE.2021; 16(9): e0255375.     CrossRef
  • Fatal Radiation Pneumonitis: Literature Review and Case Series
    Stephen Keffer, Christopher L. Guy, Elisabeth Weiss
    Advances in Radiation Oncology.2020; 5(2): 238.     CrossRef
  • Nationwide survey of radiation therapy in Japan for lung cancer complicated with interstitial lung disease
    Yasuhito Hagiwara, Yuko Nakayama, Shigehiro Kudo, Toyokazu Hayakawa, Naoki Nakamura, Yoshizumi Kitamoto, Shigeo Takahashi, Kayoko Tsujino, Nobuteru Kubo, Yukihisa Tamaki, Yasushi Nagata
    Journal of Radiation Research.2020; 61(4): 563.     CrossRef
  • Clinicopathological characteristics of lung cancer in patients with systemic sclerosis
    Minjiang Chen, Xiaoyan Liu, Yan Xu, Qing Zhou, Yuequan Shi, Dongming Zhang, Hongge Liang, Jing Zhao, Wei Zhong, Mengzhao Wang
    The Clinical Respiratory Journal.2020; 14(12): 1131.     CrossRef
  • Stereotactic Body Radiation Therapy versus Thermal Ablation for Early Stage Non–Small Cell Lung Cancer
    Melissa A. L. Vyfhuis, Pranshu Mohindra, Charles B. Simone
    Radiology.2019; 290(2): 574.     CrossRef
  • Preliminary result of definitive radiotherapy in patients with non-small cell lung cancer who have underlying idiopathic pulmonary fibrosis: comparison between X-ray and proton therapy
    Hakyoung Kim, Hongryull Pyo, Jae Myoung Noh, Woojin Lee, Byoungsuk Park, Hye Yun Park, Hongseok Yoo
    Radiation Oncology.2019;[Epub]     CrossRef
  • Neutrophil‐lymphocyte ratio and a dosimetric factor for predicting symptomatic radiation pneumonitis in non‐small‐cell lung cancer patients treated with concurrent chemoradiotherapy
    Yun Hee Lee, Hoon‐Sik Choi, Hojin Jeong, Ki Mun Kang, Jin Ho Song, Won Sup Lee, Gyeong‐Won Lee, Haa‐Na Song, Hoon‐Gu Kim, Myoung Hee Kang, Dong Yoon Rhee, Bae Kwon Jeong
    The Clinical Respiratory Journal.2018; 12(3): 1264.     CrossRef
  • Impact of Pretreatment Interstitial Lung Disease on Radiation Pneumonitis and Survival in Patients Treated With Lung Stereotactic Body Radiation Therapy (SBRT)
    Daniel Glick, Stephen Lyen, Sonja Kandel, Shane Shapera, Lisa W. Le, Patricia Lindsay, Olive Wong, Andrea Bezjak, Anthony Brade, B.C. John Cho, Andrew Hope, Alexander Sun, Meredith Giuliani
    Clinical Lung Cancer.2018; 19(2): e219.     CrossRef
  • The Association Between the Serum KL-6 Level and the Risk of Radiation Pneumonitis
    Minehiko Inomata, Seisuke Okazawa, Kenta Kambara, Shingo Imanishi, Toru Yamada, Toshiro Miwa, Kentaro Yamagishi, Kuninori Nomura, Ryuji Hayashi, Kazuyuki Tobe
    Haigan.2018; 58(1): 19.     CrossRef
  • Stereotactic body radiotherapy for second primary lung cancer and intra-parenchymal lung metastasis in patients previously treated with surgery: evaluation of indications and predictors of decreased respiratory function
    Takeaki Ishihara, Kazunari Yamada, Aya Harada, Haruhiro Yukiue, Masayuki Tanahashi, Hiroshi Niwa, Takashi Matsui, Koshi Yokomura, Yasuo Ejima, Ryohei Sasaki
    Acta Oncologica.2018; 57(9): 1232.     CrossRef
  • Incidence, Risk Factors, and Effect on Survival of Immune-related Adverse Events in Patients With Non–Small-cell Lung Cancer
    Dwight H. Owen, Lai Wei, Erin M. Bertino, Thomas Edd, Miguel A. Villalona-Calero, Kai He, Peter G. Shields, David P. Carbone, Gregory A. Otterson
    Clinical Lung Cancer.2018; 19(6): e893.     CrossRef
  • Managing the oncologic patient with suspected pneumonia in the intensive care unit
    D. Leoni, B. Encina, J. Rello
    Expert Review of Anti-infective Therapy.2016; 14(10): 943.     CrossRef
  • 13,820 View
  • 199 Download
  • 51 Web of Science
  • 46 Crossref
Close layer
High-Dose-Rate Brachytherapy for the Treatment of Vaginal Intraepithelial Neoplasia
Jin Ho Song, Joo Hwan Lee, Jong Hoon Lee, Jong Sup Park, Sook Hee Hong, Hong Seok Jang, Yeon Sil Kim, Byung Ock Choi, Sei Chul Yoon
Cancer Res Treat. 2014;46(1):74-80.   Published online January 15, 2014
DOI: https://doi.org/10.4143/crt.2014.46.1.74
AbstractAbstract PDFPubReaderePub
PURPOSE
Vaginal intraepithelial neoplasia (VAIN), a rare premalignant condition, is difficult to eradicate. We assess the effectiveness of high-dose rate intracavitary brachytherapy (HDR-ICR) in patients with VAIN or carcinoma in situ (CIS) of the vagina after hysterectomy.
MATERIALS AND METHODS
We reviewed 34 patients treated for posthysterectomy VAIN or CIS of the vagina by brachytherapy as the sole treatment. All patients underwent a coloposcopic-directed punch biopsy or had abnormal cytology, at least 3 consecutive times. All patients were treated with a vaginal cylinder applicator. The total radiation dose was mainly 40 Gy in 8 fractions during the periods of 4 weeks at a prescription point of the median 0.2 cm (range, 0 to 0.5 cm) depth from the surface of the vaginal mucosa.
RESULTS
Acute toxicity was minimal. Seven patients had grade 1/2 acute urinary and rectal complications. There were 15 cases of late toxicity, predominantly vaginal mucosal reaction in 12 patients. Of these patients, two patients suffered from grade 3 vaginal stricture and dyspareunia continuously. After a median follow-up time of 48 months (range, 4 to 122 months), there were 2 recurrences and 2 persistent diseases, in which a second-line therapy was needed. The success rate was 88.2%. The average prescription point in failure patients was 1.1 mm from the surface of the vagina compared to an average of 2.6 mm in non-recurrent patients (p=0.097).
CONCLUSION
HDR-ICR is an effective treatment method in VAIN patients. In spite of high cure rates, we should consider issues regarding vaginal toxicity and radiation techniques to reduce the occurrence of failure and toxicity.

Citations

Citations to this article as recorded by  
  • Is robotic-assisted vaginectomy a better choice in vaginal high-grade squamous intraepithelial lesions than conventional laparoscopic surgery?
    Yana Liu, Meng Mao, Jing Bai, Mingbo Cai, Qian Wang, Hanlin Fu, Mengling Zhao, Chunfang Wang, Lulu Si, Ruixia Guo
    BMC Women's Health.2024;[Epub]     CrossRef
  • Advances in the Treatment of High-Grade Stump Vaginal Intraepithelial Neoplasia after Total Hysterectomy
    俐君 刘
    Advances in Clinical Medicine.2024; 14(04): 1555.     CrossRef
  • Comprehensive evaluation of vaginal intraepithelial neoplasia development after hysterectomy: insights into diagnosis and treatment strategies
    Jiahui Wei, Yumei Wu
    Archives of Gynecology and Obstetrics.2024; 310(1): 1.     CrossRef
  • Non-Excisional therapeutic modalities in vaginal intraepithelial neoplasia
    Gonçalo Freitas, Antónia Costa
    European Journal of Obstetrics & Gynecology and Reproductive Biology.2023; 284: 175.     CrossRef
  • The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD), and the European Federation for Colposcopy (EFC) Consensus State
    Vesna Kesic, Xavier Carcopino, Mario Preti, Pedro Vieira-Baptista, Federica Bevilacqua, Jacob Bornstein, Cyrus Chargari, Maggie Cruickshank, Emre Erzeneoglu, Niccolò Gallio, Murat Gultekin, Debra Heller, Elmar Joura, Maria Kyrgiou, Tatjana Madić, François
    Journal of Lower Genital Tract Disease.2023; 27(2): 131.     CrossRef
  • The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD), and the European Federation for Colposcopy (EFC) consensus state
    Vesna Kesic, Xavier Carcopino, Mario Preti, Pedro Vieira-Baptista, Federica Bevilacqua, Jacob Bornstein, Cyrus Chargari, Maggie Cruickshank, Emre Erzeneoglu, Niccolò Gallio, Murat Gultekin, Debra Heller, Elmar Joura, Maria Kyrgiou, Tatjana Madić, François
    International Journal of Gynecological Cancer.2023; 33(4): 446.     CrossRef
  • Analysis of related factors of cervical intraepithelial neoplasia complicated with vaginal intraepithelial neoplasia
    Y.Y. Zhang, R. Xia, D. Chen, X. Zhang
    Clinical and Translational Oncology.2022; 24(5): 902.     CrossRef
  • Sexual Health Dysfunction After Radiotherapy for Gynecological Cancer: Role of Physical Rehabilitation Including Pelvic Floor Muscle Training
    Amelia Barcellini, Mattia Dominoni, Francesca Dal Mas, Helena Biancuzzi, Sara Carla Venturini, Barbara Gardella, Ester Orlandi, Kari Bø
    Frontiers in Medicine.2022;[Epub]     CrossRef
  • Clinical outcomes of laser vaporization for vaginal intraepithelial neoplasia – A 20-year retrospective review
    Mung Yuen He, Ellen Lok-man Yu, Sze Ki Hui, Yau Lung Fred Kung
    European Journal of Obstetrics & Gynecology and Reproductive Biology.2022; 277: 101.     CrossRef
  • Detection of high‐risk human papillomavirus infection and treatment of high‐grade vaginal intraepithelial neoplasia: A single‐institution study
    Hyun‐Woong Cho, Jin Hwa Hong, Jae Kwan Lee
    International Journal of Gynecology & Obstetrics.2021; 154(2): 227.     CrossRef
  • UK national survey of the management of vaginal intraepithelial neoplasia
    Mahalakshmi Gurumurthy, Simon Leeson, John Tidy, Margaret E. Cruickshank
    Journal of Obstetrics and Gynaecology.2020; 40(5): 694.     CrossRef
  • Vaginal carcinoma after cervical dysplasia
    Mikel Gorostidi, Arantza Lekuona, Arantxa Juaristi, Glauco Baiocchi
    International Journal of Gynecological Cancer.2020; 30(2): 265.     CrossRef
  • Management options for vaginal intraepithelial neoplasia
    Argirios Rountis, Vasilios Pergialiotis, Paraskevi Tsetsa, Alexandros Rodolakis, Dimitrios Haidopoulos
    International Journal of Clinical Practice.2020;[Epub]     CrossRef
  • Effect of Cyclophosphamide Treatment on Central and Effector Memory T Cells in Mice
    Marcin Włodarczyk, Elżbieta Ograczyk, Magdalena Kowalewicz-Kulbat, Magdalena Druszczyńska, Wiesława Rudnicka, Marek Fol
    International Journal of Toxicology.2018; 37(5): 373.     CrossRef
  • Total vaginectomy for refractory vaginal intraepithelial neoplasia III of the vaginal vault
    Ju Hyun Youn, Min Ah Lee, Woong Ju, Seoung Cheol Kim, Yun Hwan Kim
    Obstetrics & Gynecology Science.2016; 59(1): 71.     CrossRef
  • Brachytherapy for vaginal intraepithelial neoplasia
    Agnieszka Zolciak-Siwinska, Ewelina Gruszczynska, Joanna Jonska-Gmyrek, Anna Kulik, Wojciech Michalski
    European Journal of Obstetrics & Gynecology and Reproductive Biology.2015; 194: 73.     CrossRef
  • 13,935 View
  • 190 Download
  • 17 Web of Science
  • 16 Crossref
Close layer
Predicting Survival in Patients with Advanced Non-squamous Non-small Cell Lung Cancer: Validating the Extent of Metastasis
Dong Soo Lee, Jin Hyoung Kang, Chang Geol Lee, Seoung Jun Kim, Young Jin Choi, Kyo Young Lee, Yeon Sil Kim
Cancer Res Treat. 2013;45(2):95-102.   Published online June 30, 2013
DOI: https://doi.org/10.4143/crt.2013.45.2.95
AbstractAbstract PDFPubReaderePub
PURPOSE
A number of factors related to overall survival (OS) have been addressed in advanced non-small cell lung cancer (NSCLC). This study was conducted to determine the impact of whole-body metastatic regions on survival outcome in advanced non-squamous NSCLC.
MATERIALS AND METHODS
Between March 2005 and February 2011, 112 eligible patients with newly confirmed stage IV non-squamous NSCLC, available for epidermal growth factor receptor (EGFR) mutation status 18-21 analysis, and accessible for the determination of pretreatment whole-body metastatic regions were enrolled in this retrospective study. The total number of synchronous metastatic regions was scored according to the following disease sites: abdomen/pelvis, lung to lung/pulmonary lymphangitic spread, bone, pleura/pleural effusion/pericardial effusion, neck/axillary lymph nodes, other soft tissue, brain.
RESULTS
The median age of the cohort was 65 years (range, 31 to 88 years). The median whole-body metastatic score was 2 (range, 1 to 6), and bone and lung to lung were the most common metastatic sites. EGFR mutations were observed in 40 (35.7%) patients with a deletion in exon 19 and Leu858Arg mutation in exon 21 being detected in 16 (40.0%) and 19 (47.5%) patients, respectively. Multivariate analysis for OS revealed that treatment factors (p=0.005), performance status (p=0.006), whole-body metastatic score (p<0.001), and EGFR mutation status (p=0.095) were significantly or marginally associated with OS.
CONCLUSION
The results of the present study demonstrated that whole-body metastatic extent strongly affects survival outcome, even after adjustment for other significant variables in advanced non-squamous NSCLC. The clinical validity of more curative multimodal approaches in cohorts with limited metastases remains to be explored.

Citations

Citations to this article as recorded by  
  • Clathrin‐mediated EGFR endocytosis as a potential therapeutic strategy for overcoming primary resistance of EGFR TKI in wild‐type EGFR non‐small cell lung cancer
    Boyeon Kim, Young Soo Park, Jae Sook Sung, Jong Won Lee, Saet Byeol Lee, Yeul Hong Kim
    Cancer Medicine.2021; 10(1): 372.     CrossRef
  • Modified Glasgow Prognostic Score predicts survival among advanced non-small cell lung carcinoma patients treated with anti-PD1 agents
    Cláudia Freitas, Maria Jacob, Nuno Tavares, Natália Cruz-Martins, Conceição Souto-Moura, David Araújo, Hélder Novais-Bastos, Vanessa Santos, Gabriela Fernandes, Adriana Magalhães, Venceslau Hespanhol, Henrique Queiroga
    Anti-Cancer Drugs.2021; 32(5): 567.     CrossRef
  • O impacto da histologia do carcinoma pulmonar na frequência das metástases ósseas
    Marcelo Bragança dos Reis Oliveira, Larissa Costa Souza, Ermides Javier Garcia Sampayo, Gustavo Sobral de Carvalho, Fernanda Carvalho de Queiroz Mello, Marcos Eduardo Machado Paschoal
    Revista Brasileira de Ortopedia.2019; 54(05): 524.     CrossRef
  • Brain Metastases at Presentation in Patients With Non–Small Cell Lung Cancer
    Saiama N. Waqar, Sadaf H. Waqar, Kathryn Trinkaus, Carlos A. Gadea, Cliff G. Robinson, Jeffrey Bradley, Mark A. Watson, Varun Puri, Ramaswamy Govindan, Daniel Morgensztern
    American Journal of Clinical Oncology.2018; 41(1): 36.     CrossRef
  • Differential effects of two therapeutic cancer vaccines on short- and long-term survival populations among patients with advanced lung cancer
    Lizet Sanchez, Leacky Muchene, Patricia Lorenzo-Luaces, Carmen Viada, Pedro C. Rodriguez, Sailyn Alfonso, Tania Crombet, Elia Neninger, Ziv Shkedy, Agustin Lage
    Seminars in Oncology.2018; 45(1-2): 52.     CrossRef
  • Impact of number versus location of metastases on survival in stage IV M1b non-small cell lung cancer
    Amanda Jane Williams Gibson, Haocheng Li, Adrijana D’Silva, Roxana A. Tudor, Anifat A. Elegbede, Shannon Mary Otsuka, D. Gwyn Bebb, Winson Y. Cheung
    Medical Oncology.2018;[Epub]     CrossRef
  • PATHOLOGICAL FRACTURES DUE TO BONE METASTASES FROM LUNG CANCER: RISK FACTORS AND SURVIVAL
    Marcelo Bragança dos Reis Oliveira, Bruno de Carvalho Marques, Rosa Aurílio Matos, César Rubens da Costa Fontenelle, Fernanda Carvalho de Queiroz Mello, Marcos Eduardo Machado Paschoal
    Acta Ortopédica Brasileira.2018; 26(6): 388.     CrossRef
  • Serum lactate dehydrogenase levels at presentation in stage IV non-small cell lung cancer: predictive value of metastases and relation to survival outcomes
    Dong Soo Lee, Kyung Ran Park, Seung Joon Kim, Mi Joo Chung, Yun Hee Lee, Ji Hyun Chang, Jin Hyoung Kang, Sook Hee Hong, Myung Sin Kim, Yeon Sil Kim
    Tumor Biology.2016; 37(1): 619.     CrossRef
  • Distinctive Patterns of Initially Presenting Metastases and Clinical Outcomes According to the Histological Subtypes in Stage IV Non-Small Cell Lung Cancer
    Dong Soo Lee, Yeon S. Kim, Chul S. Kay, Sung H. Kim, Chang D. Yeo, Jin W. Kim, Seung Joon Kim, Young K. Kim, Yoon H. Ko, Jin H. Kang, Kyo Y. Lee
    Medicine.2016; 95(6): e2795.     CrossRef
  • Rare occurrence of cavitation of lung metastases following effective targeted therapy: A case report
    JIACHENG SONG, JING YU, ZHANLONG MA, SHANSHAN LU
    Oncology Letters.2016; 11(2): 1589.     CrossRef
  • Is second-line systemic chemotherapy beneficial in patients with non-small cell lung cancer (NSCLC)? A multicenter data evaluation by the Anatolian Society of Medical Oncology
    Hatice Odabas, Arife Ulas, Kubra Aydin, Mevlude Inanc, Asude Aksoy, Dogan Yazilitas, Mehmet Turkeli, Sinemis Yuksel, Ali Inal, Ahmet S. Ekinci, Alper Sevinc, Nebi S. Demirci, Mukremin Uysal, Necati Alkis, Faysal Dane, Mehmet Aliustaoglu, Mahmut Gumus
    Tumor Biology.2015; 36(12): 9641.     CrossRef
  • Clinical Correlation Between Tumor Maximal Standardized Uptake Value in Metabolic Imaging and Metastatic Tumor Characteristics in Advanced Non-small Cell Lung Cancer
    Dong Soo Lee, Seung Joon Kim, Hong Seok Jang, Ie Ryung Yoo, Kyung Ran Park, Sae Jung Na, Kyo Young Lee, Sook Hee Hong, Jin Hyoung Kang, Young Kyoon Kim, Yeon Sil Kim
    Medicine.2015; 94(32): e1304.     CrossRef
  • A case of lung cancer complicated by axillary Castleman's disease
    Manabu Kakizoe, Kousuke Suzuki, Noriyuki Saeki
    The Journal of the Japanese Association for Chest Surgery.2015; 29(6): 722.     CrossRef
  • Non-small cell lung cancer metastasis to the oral cavity: a case report
    JB Olsen, F Sim, A Chandu
    Australian Dental Journal.2014; 59(4): 520.     CrossRef
  • Lung Cancer Coexisting With Ipsilateral Pleural Effusion
    Francisco Rodriguez-Panadero, Beatriz Romero-Romero
    Lung Cancer Management.2014; 3(4): 335.     CrossRef
  • EGFR endocytosis is a novel therapeutic target in lung cancer with wild-type EGFR
    Ukhyun Jo, Kyong Hwa Park, Young Mi Whang, Jae Sook Sung, Nam Hee Won, Jong Kuk Park, Yeul Hong Kim
    Oncotarget.2014; 5(5): 1265.     CrossRef
  • 11,490 View
  • 76 Download
  • 16 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP